When do the patents on CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER expire, and when will generic CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER	ceftizoxime sodium	INJECTABLE;INJECTION	050589-001	Oct 3, 1984		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Astellas	CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER	ceftizoxime sodium	INJECTABLE;INJECTION	050589-002	Oct 3, 1984		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Cefizox in Dextrose 5% in Plastic Container is an intravenous antibiotic solution for treating moderate to severe bacterial infections. Its patent protection and market exclusivity are critical factors for investment consideration.

What is the Active Pharmaceutical Ingredient and Its Therapeutic Class?

The active pharmaceutical ingredient is Cefizox. Cefizox is a third-generation cephalosporin antibiotic. It exhibits broad-spectrum activity against many Gram-positive and Gram-negative bacteria. The drug functions by inhibiting bacterial cell wall synthesis.

What are the Approved Indications for Cefizox in Dextrose 5% in Plastic Container?

Approved indications for Cefizox in Dextrose 5% in Plastic Container include treatment of serious infections such as:

Lower Respiratory Tract Infections: Pneumonia, bronchitis.
Urinary Tract Infections: Complicated and uncomplicated pyelonephritis.
Skin and Skin Structure Infections: Cellulitis, infected wounds.
Intra-abdominal Infections: Peritonitis, cholecystitis.
Septicemia: Bloodstream infections.
Bone and Joint Infections: Osteomyelitis.

The formulation is administered intravenously, providing rapid systemic distribution.

What is the Current Patent Landscape for Cefizox and Its Formulations?

The patent landscape for Cefizox itself is largely expired. The compound Cefizox was first patented decades ago. However, patents related to specific formulations, manufacturing processes, or novel delivery systems can still provide market exclusivity.

Key patent considerations include:

Composition of Matter Patents: These are the strongest patents, covering the active molecule itself. For Cefizox, these have expired.
Formulation Patents: These patents cover specific methods of formulating the drug, such as the stabilization of Cefizox in dextrose solution, specific pH ranges, or excipient combinations. These can extend market exclusivity beyond the compound patent.
Process Patents: Patents covering novel or improved manufacturing processes for Cefizox or its formulated product.
Method of Use Patents: Patents claiming new therapeutic uses for Cefizox.

A comprehensive search of patent databases (e.g., USPTO, EPO, WIPO) is required to identify all active patents related to Cefizox and its specific intravenous formulation in a plastic container. The expiration dates of any existing formulation or process patents are crucial for determining potential generic entry and competitive pressures.

What is the Market Size and Growth Potential for Intravenous Antibiotics, Specifically Third-Generation Cephalosporins?

The global intravenous antibiotic market is substantial and projected to grow. Factors driving this growth include:

Increasing prevalence of bacterial infections: Particularly in healthcare-associated settings.
Rise in antimicrobial resistance (AMR): Leading to a demand for broader-spectrum and more potent antibiotics.
Aging global population: Older individuals are more susceptible to infections.
Advancements in healthcare infrastructure: Particularly in emerging economies.

Third-generation cephalosporins, including Cefizox, are a cornerstone of empirical antibiotic therapy for many serious infections due to their efficacy and relatively favorable safety profiles. However, the market is also characterized by significant competition from other antibiotic classes and the emergence of generics.

Specific market data for "Cefizox in Dextrose 5% in Plastic Container" as a distinct product is challenging to isolate from the broader cephalosporin or intravenous antibiotic markets. However, estimates for the global cephalosporin market indicate a significant valuation, projected to reach billions of dollars. Growth rates typically range from 4% to 7% annually, influenced by infection rates and the development of new resistance patterns [1].

What is the Competitive Landscape for Cefizox in Dextrose 5% in Plastic Container?

The competitive landscape is multifaceted, involving:

Branded Cefizox Products: Original innovators and their licensed manufacturers.
Generic Cefizox Products: Once primary patents expire, generic manufacturers can enter the market, significantly driving down prices. The availability of generic Cefizox injectables is widespread.
Other Third-Generation Cephalosporins: Drugs such as ceftriaxone, cefotaxime, and ceftazidime compete directly based on spectrum of activity, dosing regimens, and cost.
Other Antibiotic Classes: For specific indications, other classes like carbapenems, fluoroquinolones, or piperacillin-tazobactam may be used, depending on local resistance patterns and clinical guidelines.
Newer Antibiotics: The development of novel antibiotics with activity against multidrug-resistant organisms (MDROs) poses a long-term competitive threat.

The specific formulation in a plastic container (as opposed to glass vials) may offer advantages in terms of portability, shatter resistance, and potentially ease of administration, which could be a minor differentiator.

What are the Key Regulatory Considerations and Approvals?

Regulatory approval for Cefizox in Dextrose 5% in Plastic Container is required from relevant health authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Key regulatory aspects include:

New Drug Application (NDA) or Marketing Authorization Application (MAA): Demonstrating safety, efficacy, and quality.
Abbreviated New Drug Application (ANDA) for Generics: Generic versions must demonstrate bioequivalence to the reference listed drug.
Good Manufacturing Practices (GMP): Adherence to strict manufacturing standards for quality and consistency.
Labeling and Prescribing Information: Compliance with regulations regarding drug information for healthcare professionals and patients.
Post-Marketing Surveillance: Ongoing monitoring of the drug's safety and effectiveness in the real world.

The plastic container itself may be subject to specific regulatory scrutiny regarding leachables and extractables, and compatibility with the drug solution.

What are the Primary Risks and Opportunities for Investors?

Risks:

Generic Competition: The primary risk for any drug with expired composition of matter patents is the rapid entry of generic competitors, leading to price erosion and reduced profit margins.
Antimicrobial Resistance: The development of resistance to Cefizox or cephalosporins in general can diminish its clinical utility and market demand.
Emergence of Newer Agents: Novel antibiotics targeting resistant pathogens may displace older drugs like Cefizox.
Regulatory Changes: Evolving regulatory requirements or unfavorable policy changes regarding antibiotic pricing or reimbursement.
Manufacturing and Supply Chain Issues: Disruptions in the supply chain for raw materials or finished product manufacturing.
Safety Concerns: Although generally well-tolerated, rare but serious adverse events can impact market perception and sales.

Opportunities:

Growing Demand for IV Antibiotics: The persistent need for effective intravenous treatments for serious infections, especially in hospital settings.
Market Penetration in Emerging Economies: Untapped potential in regions with developing healthcare infrastructure and increasing access to medicines.
Cost-Effectiveness: Cefizox, particularly generic versions, often represents a cost-effective treatment option compared to newer, more expensive antibiotics.
Niche Market Advantages: If specific formulation patents offer extended exclusivity or the plastic container provides a demonstrable administration benefit, this could create a competitive edge.
Portfolio Diversification: For manufacturers or distributors, Cefizox can be part of a broader portfolio of essential antibiotics, contributing to stable revenue streams.

What are the Key Financial Metrics and Valuation Considerations?

Valuation of a product like Cefizox in Dextrose 5% in Plastic Container will heavily depend on its market status (branded vs. generic), remaining patent life (if any for formulation/process), sales volume, pricing, cost of goods sold (COGS), and market share.

Key financial metrics to consider:

Revenue: Annual sales generated by the product.
Gross Margin: Revenue minus COGS.
Operating Expenses: Marketing, sales, R&D (if any ongoing), and administrative costs associated with the product.
EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization): A measure of profitability.
Market Share: Percentage of the relevant antibiotic market held by the product.
Pricing Trends: Historical and projected price changes, particularly in response to generic competition.

Valuation methodologies can include:

Discounted Cash Flow (DCF): Projecting future cash flows and discounting them back to the present value, considering the drug's lifecycle and competitive pressures.
Multiples Analysis: Comparing the company or product's valuation to similar publicly traded companies or recent transactions using metrics like revenue multiples or EBITDA multiples.
Asset-Based Valuation: Less common for pharmaceuticals unless considering manufacturing facilities.

For a product nearing patent expiry or already facing generic competition, valuation will likely reflect a mature or declining revenue stream, emphasizing current profitability and cash flow generation rather than future growth potential.

Key Takeaways

Cefizox in Dextrose 5% in Plastic Container is a mature intravenous antibiotic with established indications. The primary driver for investment attractiveness is the product's remaining market exclusivity, if any, stemming from formulation or process patents, and its competitive positioning against other third-generation cephalosporins and emerging antibiotic classes. The market for intravenous antibiotics is expanding due to rising infection rates and antimicrobial resistance, yet is characterized by intense generic competition and price pressure. Robust due diligence on the specific patent landscape, regulatory status, and market dynamics is imperative for informed investment decisions.

Frequently Asked Questions

1. Are there any active patents protecting Cefizox in Dextrose 5% in Plastic Container from generic competition in major markets like the United States?

Determining active patents requires a detailed search of the USPTO Orange Book and patent databases. While the compound patent for Cefizox has expired, specific formulation patents (e.g., for the plastic container, stabilization, or manufacturing process) could still be in force. The absence of such patents would indicate a high risk of generic entry.

2. What is the typical price differential between branded Cefizox injectables and generic versions?

Price differentials can be substantial, often ranging from 50% to over 90% reduction for generic versions compared to the branded product, especially several years after generic market entry. This depends on the number of generic competitors and payer reimbursement policies.

3. How does the use of a plastic container, as opposed to a glass vial, impact the marketability and cost of Cefizox?

Plastic containers offer advantages such as reduced breakage risk, lower weight, and potential for pre-mixed formulations, which can streamline administration. These benefits may justify a slight premium, but the primary cost driver remains the active pharmaceutical ingredient and manufacturing scale. The impact on marketability is incremental unless it enables novel distribution or administration channels.

4. What is the current standard of care for infections typically treated by Cefizox, and how might this evolve?

Standard of care often involves empirical treatment with broad-spectrum agents, including third-generation cephalosporins like Cefizox, followed by targeted therapy based on susceptibility testing. Evolution may lead to increased use of newer agents for resistant infections or de-escalation to narrower-spectrum antibiotics where appropriate. Guidelines from infectious disease societies (e.g., IDSA) are critical indicators.

5. What are the primary regulatory hurdles for introducing a new generic version of Cefizox in Dextrose 5% in Plastic Container?

A generic manufacturer must submit an Abbreviated New Drug Application (ANDA) to the FDA (or equivalent). This involves demonstrating bioequivalence to the reference listed drug, ensuring the active ingredient, strength, dosage form, and route of administration are the same. Manufacturing facilities must also adhere to current Good Manufacturing Practices (cGMP).

Citations

[1] Grand View Research. (2023). Cephalosporin Market Size, Share & Trends Analysis Report By Type (First, Second, Third, Fourth, Fifth Generation), By Application (Respiratory Tract Infections, Urinary Tract Infections, Skin and Soft Tissue Infections, Others), By Region, And Segment Forecasts, 2024-2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/cephalosporin-market

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile

When do Cefizox In Dextrose 5% In Plastic Container patents expire, and when can generic versions of Cefizox In Dextrose 5% In Plastic Container launch?

AI Deep Research

Questions you can ask:

Summary for CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

US Patents and Regulatory Information for CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER: Investment Analysis and Patent Landscape